• drapreau en
  • drapreau fr


  • Orateurs Invités

  • Jean-Emmanuel Sarry (Cancer Research Center of Toulouse)



    Klaus Pantel (University Medical Center Hamburg-Eppendorf)

    Prof Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg- Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). The pioneer work of Prof Pantel in the field of cancer micrometastasis, circulating tumor cells and circulating nucleic acids (ctDNA, microRNAs) is reflected by more than 400 publications in excellent high ranking biomedical and scientific journals (incl. NEJM, Lancet, Nature Journals, Cancer Cell, Science Translational Medicine, Cancer Discovery, PNAS, JCO, JNCI, Cancer Res.) and has been awarded the AACR Outstanding Investigator Award 2010, German Cancer Award 2010, and ERC Advanced Investigator Grant 2011. Moreover, Prof Pantel coordinates the European TRANSCAN group “CTC-SCAN”, the European IMI consortium CANCER-ID (www.cancer-id.eu) on blood-based “Liquid Biopsies” and serves on the Editorial Boards of international cancer journals (e.g., Breast Cancer Res., Cancer Res.).


    Matthew G Vander Heiden (MIT)

    Matthew Vander Heiden is an Associate Professor in the Department of Biology at the Massachusetts Institute of Technology, and Associate Director of the Koch Institute for Integrative Cancer Research.  He is also an HHMI Faculty Scholar, an Institute Member of the Broad Institute of Harvard and MIT, and an Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School.  Dr. Vander Heiden received his MD and PhD degree from the University of Chicago.  He also completed clinical training in Internal Medicine and Medical Oncology at the Brigham and Women’s Hospital / Dana-Farber Cancer Institute prior to completing a post-doctoral fellowship at Harvard Medical School.  His laboratory studies how metabolism is regulated to meet the needs of cells in different physiological situations.  A major focus of his research is the role of metabolism in cancer, and particularly how metabolic pathways support cancer cell proliferation and survival. Using a combination of biochemistry, molecular biology and mouse models, the aim of the Vander Heiden laboratory is to understand how metabolism influences different stages of tumor biology with a goal to improve cancer treatment in the clinic.
     


    Pierre Sonveaux (Université Catholique de Louvain)

    Pierre Sonveaux, PhD, is the Director of the team of Tumor Metabolism (TUMETABO) at the Pole of Pharmacology & Therapeutics of the IREC Institute at the Université catholique de Louvain (UCL) Medical School in Brussels, Belgium. He is Professor of Pharmacology and Senior Research Associate of the Belgian National Fund for Scientific Research (F.R.S.-FNRS). Prof. Sonveaux is President of the International Society of Tumor Metabolism (ISCaM) and a member of the Editorial Boards of Cancer Research, Frontiers in Pharmacology and Cell Stress. Research by his team aim to characterize cancer metabolism in tumors as an organ in order to identify and validate new anticancer targets. Based on collaborative work, key achievements include the identification of a metabolic symbiosis in cancer, and of mitochondrial superoxide as an amenable target for the prevention of cancer metastasis. Prof. Sonveaux received several awards, including the ESTRO-VARIAN-Juliana Denekamp Award 2007, the FECS-EJC Award 2007, the Galien Prize in Pharmacology 2010, the EACR Highly Commended Award in 2010 and the AstraZeneca Prize in Oncology 2016. He is Officer of the Walloon Merit Order, Belgium.
     

     


    Gaëlle Legube (Center for Integrative Biology, Toulouse)



    Jan Hoeijmakers (Erasmus University of Rotterdam)

    Jan Hoeijmakers started the molecular analysis of DNA repair in mammals at the Dept. of Genetics (Erasmus Univ. Rotterdam) in 1981. He cloned the first of many human DNA repair genes, allowing elucidation of the underlying mechanisms and the basis of human repair syndromes, such as the cancer-prone xeroderma pigmentosum disorder and the severe neurodevelopmental conditions Cockayne syndrome and trichothiodystrophy. His team pioneered DNA repair dynamics in living cells using novel imaging technologies, generated numerous mouse repair mutants, discovered a strong connection between accumulation of DNA damage and accelerated aging and a trade-off between cancer and aging. The mouse mutants appeared superior models for Alzheimer’s disease addressing a tremendous unmet medical need. Accumulation of unrepaired DNA damage causing premature cell death and senescence also triggered an anti-aging ‘survival response’ which enhances maintenance at the expense of growth resembling the longevity response by dietary restriction. Remarkably, subjecting repair-deficient progeroid mice to actual dietary restriction tripled their lifespan, drastically retarding DNA damage accumulation and accelerated aging most impressively neurodegeneration. In addition he discoverd that accelerated and normal aging are associated with transcriptional stress due to stochastic DNA damage affecting gene expression and that dietary restriction counteracts the declining transcriptional output. These findings open perspectives for preventive interventions for healthy aging, reducing cancer and many aging-related diseases including neurodegeneration, and for therapy of human genome instability syndromes. For his work Jan Hoeijmakers received many prizes and awards.
     


    Mark O'Connor (Astra-Zeneca)

    Mark is Chief Scientist in Oncology at AstraZeneca (AZ), based in Cambridge, United Kingdom, where he heads up the DNA Damage Response (DDR) strategic biology area. He earned a Ph.D. in biochemistry from Bristol University and carried out his postdoctoral research at the Institute of Molecular and Cell Biology in Singapore, working on the biology of human papillomavirus and the link to cervical cancer
    In 1999, Mark returned to the UK to become research team leader at the Cambridge start-up and DDR specialist biotech company KuDOS, and was promoted to Chief Scientist there in 2009. Since 2006, when AstraZeneca acquired KuDOS, Mark has provided scientific leadership on olaparib (Lynparza), the first-in-class oral poly (ADP-ribose) polymerase (PARP) inhibitor, through its transfer to AZ and approval in the United States and Europe in 2014. Mark also championed the in-licensing of the WEE1 inhibitor (AZD1775) in 2013 and has played a key role in the growth of DDR within AZ to an industry-leading portfolio comprising seven DDR projects with six inhibitors currently in clinical development.  As well as being a named inventor on multiple patents, Mark has publications that include papers in Cell, Molecular Cell, Nature Cell Biology and New England Journal of Medicine.
     


    Steve Jackson (University of Cambridge)

    Steve Jackson FRS, FMedSci is University of Cambridge Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute. Through his academic research (h-index 121; Google Scholar), Steve has identified key principles by which cells respond to and repair DNA damage. In doing so, he identified many DNA repair proteins, established how they function, and helped define how their dysfunction leads to cancer and other age-related diseases. Steve has received various prizes, including the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, the 2016 AH. Heineken Prize for Medicine, and the 2017 Genome Stability Network Medal.
    To translate his work towards patient benefit, Steve founded and then scientifically led the drug-discovery company KuDOS Pharmaceuticals Ltd., which was subsequently acquired by AstraZeneca. Several KuDOS-generated drugs are currently in clinical trials. The most advanced of these drugs, olaparib/LynparzaTM, inhibits the DNA-repair enzyme PARP, and enhances cancer-cell killing by radiotherapy and chemotherapies. Moreover, Steve and colleagues showed that PARP inhibitors exhibit striking cytotoxicity towards cancer cells lacking BRCA1 or BRCA2 function. This work thus validated a therapeutic concept that Steve articulated in his 1997 KuDOS Business Plan: killing cancer cells with defects in one DNA repair system by targeting their functional dependency on another DNA repair system, but having little effect on normal cells with the full DNA-repair repertoire.
    In 2014, olaparib/Lynparza received FDA and EMA approval for treating ovarian cancers with BRCA1/2 mutations, and is now prescribed in ~50 countries worldwide. Lynparza/olaparib is the world’s first marketed DNA-repair-enzyme inhibitor, the first marketed PARP inhibitor, the first drug exploiting the so-called “synthetic lethality” principle, and the first cancer medicine targeting inherited predisposition. Ongoing clinical trials are highlighting exciting potential for olaparib and other PARP inhibitors in many other cancers.
    In 2010, Steve founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit recent advances in protein ubiquitylation and deubiquitylation to derive new medicines for cancer, neurodegenerative disorders and other diseases. Steve’s academic laboratory is currently further defining mechanisms of DNA repair and associated processes, with a view to identifying new therapeutic opportunities.
     


    François Payre (Center for Integrative Biology, Toulouse)



    Maarten van Lohuizen (The Netherlands Cancer Institute)



    Maite Huarte (University of Navarra)

    Dr. Maite Huarte obtained her PhD at National Center for Biotechnology (CSIC) in Universidad Autónoma de Madrid. Her postdoctoral work was carried out first in Harvard Medical School in Dr. Yang Shi’s laboratory where she identified new histone demethylase enzymes and their contribution to the epigenetic landscape of cells. Later, she worked in John Rinn’s laboratory at the Broad Institute of Harvard and MIT, studying the role of long noncoding RNAs (lncRNAs) in gene regulation.

    Since 2011 she leads a research group at CIMA (University of Navarra) that investigates how long noncoding RNAs contribute to the mechanisms of gene regulation at the epigenetic and non-epigenetic levels in cancer cells. To reach these goals, they combine functional genomics with molecular and cell biology techniques, in vivo studies, as well as the analysis of patient samples.


     


    Ramiro Garzon (The Ohio State University)

    Ramiro Garzon is an Associate Professor of Medicine in the Division of Hematology, and a co-leader of the Leukemia Research Program at The Ohio State University (OSU) Comprehensive Cancer Center, Columbus, Ohio. He received his M.D. from the National University School of Medicine, Cordoba, Argentina. He trained in the Medicine program at Yale affiliated Danbury Hospital, Connecticut and subsequently completed a hematology/oncology fellowship at Thomas Jefferson University, Philadelphia. His research focuses on noncoding RNA expression and function in hematopoiesis and leukemia. He has published more than 90 peer-reviewed articles and is the principal investigator of several federal research grants. He has received the Kimmel Translational award, the Leukemia and Lymphoma Scholar Award and the American Cancer Society Research Scholar Award. He is currently a permanent member of the Clinical Oncology Study section at the National Institute of Health and a member of the Scientific Committee on Transplantation Biology and Cellular Therapies of eth American Society of Hematology.
     


    Jean-Philippe Girard (Institute of Pharmacology and Structural Biology, Toulouse)



    Jolanda De Vries (Radboud University Nijmegen)



    Nathalie Rufer (University of Lausanne)

    Dr. Nathalie Rufer received her PhD from the University of Geneva in 1996. She carried out her post-doctoral work at the Terry Fox Laboratory in Vancouver (Canada) before joining in 2001, the Swiss Institute for Cancer Research (ISREC) as an associate scientist within the Lausanne Oncology program. Since 2009, she has been appointed by the Lausanne University Hospital Center (CHUV), and affiliated to the Ludwig Center for Cancer Research. In 2012, Nathalie Rufer finished her full education in clinical medicine at the University of Lausanne and joined the Department of Oncology led by Prof. George Coukos. Since January 2013, she is extending her research activities together with her clinical education in internal medicine, in oncology and currently in hematology.
     
    The Rufer lab studies T cell responses against tumor antigens in cancer patients following therapeutic vaccination and naturally occurring immune responses, with the major goals to advance our knowledge of T cell mediated protection from human disease and to improve T cell based therapy in the fight against cancer. Three aspects of T cell-mediated immunity are of prime interest to us; (i) the identification of T cell attributes (e.g. memory versus effector) following immune-based therapy in cancer patients, (ii) the T cell clonotype repertoire and its persistence over time against cancer and chronic infection with herpes viruses, and (iii) TCR-pMHC binding interactions and structure/function relationships of tumor- and virus-specific CD8 T cell clonotypes combined with novel technologies (i.e. NTAmers). Another main focus of our team lies in the development of adoptive cell transfer strategies using engineered T cells. Specifically, we are investigating on approaches to optimize the TCRs with the aim to increase their affinities to cognate tumor antigens, while characterizing the regulatory mechanisms involved in T cell activation, signaling and subsequent function in those TCR-engineered T cells. Understanding TCR-pMHC affinity-mediated regulations and identifying optimized tumor antigen-specific TCRs directly contributes to the rational development of adoptive cell therapy.  
     


    Gillies McKenna (University of Oxford)

    A native of Scotland, Professor Gillies McKenna graduated in Zoology in 1972 from the University of Edinburgh; he then studied in the US for an M.D. and a Ph.D. in Cell Biology from Albert Einstein College of Medicine in New York. After postgraduate training at Johns Hopkins Hospital and the US National Cancer Institute, Professor McKenna joined the Faculty of the University of Pennsylvania School of Medicine in Philadelphia in 1987, where he rose to become the Henry K. Pancoast Professor and Chairman of Radiation Oncology. His major research interest is the study of the molecular mechanisms underlying the resistance of some cancers to treatment with radiation or with chemotherapy. He is particularly interested in developing strategies to render some of the most resistant tumours more  sensitive  to  treatment  and  is  working  to  bring  some  of  his  research discoveries into clinical trial in our area. Professor McKenna has received several awards and honours including a Scholar’s Award from the Radiological Society of North America, a Career Development Award from the American Cancer Society, the Weiss medal from the Association for Radiation Research, the Röntgen Medal from the Deutches Röntgen Museum, Germany and most recently the Gold Medal from the Royal College of Radiologists. He was a member of the Board of Scientific Advisors of the US National Cancer Institute. Professor McKenna moved to Oxford in 2005 and is currently the Director of the CRUK/MRC Oxford Institute for Radiation Oncology. He was Head of the Department of Oncology from 2010 to April 2017. He works closely and serves on scientific boards with external funding bodies and partners.  He is a Fellow of the Royal College of Radiologists, the Academy of Medical Sciences and of the Institute of Biology.
     


    Jim Metz (University of Pennsylvania)

    James M. Metz, MD, Chair of the Department of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania.
     
    Dr. Metz is a radiation oncologist who specializes in the treatment of gastrointestinal malignancies and the retreatment of previously irradiated tumors. He has led numerous clinical trials in gastrointestinal cancer with a particular interest in maintaining normal organ function. His clinical research emphasizes multimodality therapies for locally advanced gastrointestinal malignancies. Dr. Metz led the development of the Roberts Proton Therapy Center, the largest proton center in the world, which opened in 2010. He has been an international leader in the integration of proton therapy in the cancer treatment paradigm.
     
    He has held a series of administrative positions within the department, beginning in 2005, when he was appointed Director of Clinical Operations. In 2009, he was appointed Vice Chair of the Clinical Division in Radiation Oncology, and in 2010 became the Director of Quality Assurance and Quality Improvement. In 2014, he was appointed Vice Chair of the department. He has served as Professor of Radiation Oncology at the Perelman School of Medicine and was the Associate Director for Clinical Services and Programs at the Abramson Cancer Center of the University of Pennsylvania.
     
    As the long time Editor-in-Chief (and now Executive Director) of OncoLink, an award winning website and resource for cancer information, Dr. Metz pioneered the use of online cancer survivorship care plans and web-based cancer education and information. OncoLink (www.OncoLink.Penn.edu) has been named on numerous occasions as one of the Top 10 medical websites in the world by the National Library of Medicine.
     
    Dr. Metz is board certified in radiation oncology and is a member of the American Society of Clinical Oncology (ASCO) and the American Society of Therapeutic Radiation Oncology (ASTRO).
     


    Julien Mazières (IUCT-Rangueil Larrey, Cancer Research Center of Toulouse)



    Céleste Lebbé (Hôpital Saint-Louis, APHP)



    Nicolas Meyer (IUCT-Oncopole, Cancer Research Center of Toulouse)



    Richard Marais (Cancer Research UK Manchester Institute)

    Professor Marais is the Director of the CRUK Manchester Institute at The University of Manchester and a Professor of Molecular Biology. He has advanced our understanding of the role of BRAF in cancer and in 2004 he validated mutant BRAF as a therapeutic target in melanoma. He has since pioneered translational research in melanoma, studying basic biology to understand the mechanisms of resistance to targeted therapies. He was a member of the 2012 winning team for the AACR Team Science Award for its cancer drug discovery programme and more recently has developed anticancer drugs that target RAF kinases. In 2017, he received the Translational and Clinical Research Award from The ARC Foundation Léopold Griffuel Awards and an Outstanding Research Award from The Society of Melanoma Research. His research has contributed to public health information regarding the use of sunscreen and the need to combine this with other sun avoidance strategies to reduce the risk of developing melanoma. Professor Marais continues to focus on understanding the pathological basis of melanoma to deliver benefit to patients.
     

  • AGENCE PCO PARTENAIRE DE L'ÉVÉNEMENT :
    INSIGHT OUTSIDE
    Comité local d'organisation :
    GIP IUCT
    1 Av. Irène Joliot-Curie
    31100 Toulouse
    * prix depuis ligne fixe opérateur historique, une surtaxe peut être appliquée selon les opérateurs, décompte à la seconde au delà des 45 premières secondes.

    Conformément à la loi Informatique et Libertés, vous disposez d'un droit d'accès et de rectification aux données personnelles vous concernant en vous adressant à INSIGHT OUTSIDE 39 chemin du vieux chêne, 38240 Meylan / France. Conformément à la loi pour la Confiance dans l'Economie numérique du 21 juin 2004, vous pouvez également vous opposer à l'utilisation de vos coordonnées, en envoyant un simple courrier à l'adresse ci-dessus.

    © 2005 - 2017 Insight Outside